Compare Enveric Biosciences Inc (ENVB) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Icl Group Ltd — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Icl Group Ltd trades at $5.01 (market cap $6.47B). The key difference: Icl Group Ltd is far larger — about 951.5× Enveric Biosciences Inc's market cap, and Icl Group Ltd pays a 4.11% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Icl Group Ltd for 56 Days on average.
| ENVB | ICL | |
|---|---|---|
Market Cap | $6.80M | $6.47B |
Volume | 64,867 | 1,387,140 |
Sector | Health | Basic Materials |
52-Week High | $10.80 | $6.84 |
52-Week Low | $1.27 | $4.80 |
Typical Hold Time | 14 Days | 56 Days |
Enterprise Value | -$1.49M | $9.11B |
Dividend Yield | — | 4.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
ICL trades at $5.08 with no daily change, showing stable but muted short-term performance. The stock exhibits bearish technical signals with declining revenue and net income margins over recent years, though Q2 2026 earnings beat expectations. Analyst consensus is entirely neutral with 4 hold ratings and a $6.08 price target, suggesting limited near-term upside. Recent news highlights dividend stability and cost-transformation initiatives amid fertilizer industry headwinds.
ICL faces mixed prospects with stable cash flows and dividend payments offset by profitability pressures. The 19.7% upside to consensus target offers moderate potential, but investors must weigh declining margins against operational efficiency efforts. Key risks include input cost inflation and reduced fertilizer demand, requiring careful monitoring of Q3 2026 results and cost program execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
